dinitramine: structure
ID Source | ID |
---|---|
PubMed CID | 34468 |
CHEMBL ID | 1223066 |
CHEBI ID | 81959 |
SCHEMBL ID | 66368 |
MeSH ID | M0042513 |
Synonym |
---|
CHEMBL1223066 |
chebi:81959 , |
dinitramine [ansi:bsi:iso] |
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine |
cobex (herbicide) |
1,3-benzenediamine, n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)- |
n3,n3-diethyl-2,4-dinitro-6-trifluoromethyl-m-phenylenediamine |
3-diethylamino-2,4-dinitro-6-trifluoromethylaniline |
hsdb 6617 |
ai3-62693 |
epa pesticide chemical code 102301 |
n(3),n(3)-diethyl-2,4-dinitro-6-trifluoromethyl-m-phenylenediamine |
n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)-1,3-benzenediamine |
n4,n4-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine |
caswell no. 335c |
cobex |
brn 2822138 |
1,3-benzenediamine, n(sup 3),n(sup 3)-diethyl-2,4-dinitro-6-(trifluoromethyl)- |
n1,n1-diethyl-2,6-dinitro-4-trifluoromethyl-m-phenylenediamine |
usb-3584 |
dinitramine |
n(sup 3),n(sup 3)-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine |
n,n-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine [iso] |
toluene-2,4-diamine, n(sup 4),n(sup 4)-diethyl-3,5-dinitro-alpha,alpha,alpha-trifluoro- |
n(sup 4),n(sup 4)-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine |
cobeko |
cobexo |
einecs 249-419-2 |
toluene-2,4-diamine, n(sup 4),n(sup 4)-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitro- |
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)benzene-1,3-diamine |
n,n-diethyl-2,6-dinitro-4-(trifluoromethyl)benzene-1,3-diamine |
3-n,3-n-diethyl-2,4-dinitro-6-(trifluoromethyl)benzene-1,3-diamine |
usb 3584 |
29091-05-2 |
C18785 |
tox21_302221 |
cas-29091-05-2 |
NCGC00255511-01 |
dtxsid9040265 , |
dtxcid7020265 |
unii-xhq6d15979 |
1,3-benzenediamine, n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)- |
n,n-diethyl-alpha,alpha,alpha-trifluoro-3,5-dinitrotoluene-2,4-diamine |
xhq6d15979 , |
FT-0630545 |
AKOS015888327 |
n(sup 1),n(sup 1)-diethyl-2,6-dinitro-4-trifluoromethyl-m-phenylenediamine |
dinitramine [iso] |
kobex |
dinitramine [hsdb] |
SCHEMBL66368 |
W-107007 |
toluene-2,4-diamine, n4,n4-diethyl-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitro- |
n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-phenylenediamine |
toluene-2,4-diamine, n4,n4-diethyl-3,5-dinitro-.alpha.,.alpha.,.alpha.-trifluoro- |
n4,n4-diethyl-.alpha.,.alpha.,.alpha.-trifluoro-3,5-dinitrotoluene, 2,4-diamine |
dinitramine, pestanal(r), analytical standard |
cobex;n3,n3-diethyl-2,4-dinitro-6-(trifluoromethyl)-1,3-benzenediamine |
n1,n1-diethyl-2,6-dinitro-4-(trifluoromethyl)benzene-1,3-diamine |
Q27155666 |
Dinitramine is a dinitroaniline herbicide that is particularly toxic to aquatic organisms.
Excerpt | Reference | Relevance |
---|---|---|
"Dinitramine is a dinitroaniline herbicide that is particularly toxic to aquatic organisms." | ( Dinitramine induces implantation failure by cell cycle arrest and mitochondrial dysfunction in porcine trophectoderm and luminal epithelial cells. An, G; Lim, W; Park, J; Song, G, 2022) | 2.89 |
Excerpt | Reference | Relevance |
---|---|---|
"Dinitramine has an amine group at the meta position not present in any of the other dinitroanilines tested here that is predicted to form hydrogen bonds with residues Arg2 and Gln133 according to docking data." | ( Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. Gu, F; Li, C; Ma, C; Morrissette, N; Ochoa, R; Sept, D; Tran, J; Werbovetz, K, 2010) | 1.08 |
"Dinitramine has an amine group at the meta position not present in any of the other dinitroanilines tested here that is predicted to form hydrogen bonds with residues Arg2 and Gln133 according to docking data." | ( Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. Gu, F; Li, C; Ma, C; Morrissette, N; Ochoa, R; Sept, D; Tran, J; Werbovetz, K, 2010) | 1.08 |
Class | Description |
---|---|
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 27.3060 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 15.6892 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 42.6519 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743054; AID743063 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 27.4601 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 27.3060 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 44.3353 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 1.4493 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 23.1001 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 6.8590 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 47.6413 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743091 |
caspase-3 | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 34.3762 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 13.6854 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 46.3037 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 113.0040 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 34.3762 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 34.3762 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID522810 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522812 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522818 | Induction of parasite shape change Toxoplasma gondii RH infected in HFF cells at 0.25 uM by phase contrast microscopy | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522815 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522808 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522816 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522809 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522813 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522811 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522807 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522806 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID502117 | Antimicrobial activity against Toxoplasma gondii infected in HFF after 8 days by plaque assay | 2010 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17 | Synthesis and evaluation of oryzalin analogs against Toxoplasma gondii. |
AID522805 | Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522814 | Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
AID522817 | Induction of parasite microtubule disruption Toxoplasma gondii RH infected in HFF cells by antitubulin antibody staining | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (30.77) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 4 (30.77) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.07) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |